Updates are available Correction dated 2021-12-08
Click to view Correction: https://doi.org/10.1038/s42003-021-02929-x
-
Authors
Anderson, Brett D. http://orcid.org/0000-0002-5537-8663
Nelson, Erek D. http://orcid.org/0000-0001-5853-9779
Joo, DongJin
Amiot, Bruce P. http://orcid.org/0000-0002-9450-9179
Katane, Aleksandr A.
Mendenhall, Alyssa
Steiner, Benjamin G.
Stumbras, Aron R.
Nelson, Victoria L.
Palumbo, R. Noelle
Gilbert, Thomas W.
Davidow, Dominique S. http://orcid.org/0000-0001-8105-7110
Ross, Jeffrey J. http://orcid.org/0000-0001-8185-5905
Nyberg, Scott L. http://orcid.org/0000-0002-5005-3050
- License Information
-
More Information
Article History
Received: 11 November 2019
Accepted: 8 September 2021
First Online: 7 October 2021
Change Date: 8 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-021-02929-x
Competing interests
: The authors declare the following competing interests: B.D.A., A.A.K., A.M., B.G.S., A.R.S., V.L.N., R.N.P., T.W.G., D.S.D., and J.J.R. are employees of Miromatrix Inc. Miromatrix Inc. is a publicly funded company and owns the exclusive patent rights for the perfusion decellularization and recellularization technologies utilized in this study. The remaining authors declare no competing interests.
